Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Niagen Bioscience Inc
NAGE
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.01
-0.055
-2.66%
In chiusura: Nov 16, 4:00 PM EST
$1.96
-0.05
-2.49%
Post-mercato: 7:21 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Niagen Bioscience Financials
Niagen Bioscience (NAGE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Niagen Bioscience Raises FY2026 Sales Guidance from $138.982M-$145.299M to $145.299M-$151.616M vs $130.410M Est
Niagen Bioscience (NASDAQ:NAGE) raises FY2026 sales outlook from $138.982 million-$145.299 million to $145.299 million-$151.616 million vs $130.410 million estimate.
Benzinga Newsdesk
PRO
Niagen Bioscience Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $27.192M Miss $32.062M Estimate
Niagen Bioscience (NASDAQ:NAGE) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.02 by 150 percent. This is a 120 percent decrease over earnings of $0.05 per share from
Benzinga Newsdesk
PRO
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.
Benzinga Newsdesk
PRO
Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M Estimate
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 75 percent decrease over earnings of $0.04 per share from the
Benzinga Newsdesk
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)
Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.
Eva Mathew
Earnings Scheduled For May 6, 2026
Benzinga Insights